Funds See Spike In Biotech Single Stock Liquidity As Takeovers Emerge
Mar 5, 2015
Fund managers are seeing a spike in liquidity in biotech single stock options amid an increase in takeover announcements and merger agreements in the sector. One fund, for example, has increased its derivatives exposure to the sector in its special situations portfolio during the first two months of 2015.
Restricted content
You must be an EQD+ subscriber to view this page. Either sign in or see below on how to request a trial.
Get access now
Start your 7 day free trial.
You’ll be charged at the conclusion of your trial.
Cancel at any time.
Questions? Need access for multiple users?
Contact eqdplus@eqderivatives.com